JINLING PHARM. branch received the acceptance notice for Olaratumab tablets
JINLING PHARM.'s subsidiary Nanjing JINLING Pharmaceutical Factory recently received the acceptance notice from the National Medical Products Administration for the application of domestic production drug registration clinical trials for Elagolix tablets. Elagolix is a GnRH antagonist that was approved by the FDA in 2018, specifically for the treatment of moderate to severe pain associated with endometriosis. If the clinical trials go smoothly, it will enhance the company's product line and competitiveness
According to the Zhitong Finance APP, JINLING PHARM. (000919.SZ) announced that its subsidiary, Nanjing JINLING Pharmaceutical Factory, recently received the acceptance notice from the National Medical Products Administration for the application of Olaragolix tablets (CYHL2500117, CYHL2500118), which pertains to the registration of clinical trials for domestically produced drugs.
Olaragolix is an oral gonadotropin-releasing hormone (GnRH) antagonist that was approved by the FDA for marketing on July 23, 2018. It is the first oral GnRH receptor antagonist approved specifically for the treatment of moderate to severe pain associated with endometriosis. If the clinical trials for this product progress smoothly, it will enrich and enhance the company's product line layout and improve the competitiveness of the company's products
